Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot showed patients lost 22% of their bodyweight in a clinical trial. Shares were 9.5% higher ...

Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical development planned.

Just because Wall Street likes a stock doesn't mean it's a great pick. However, it's not a bad idea to at least consider how ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...